Skip to content

Repeated transcranial magnetic stimulation augmenting the treatment of schizophrenia with modified electroconvulsive therapy in the acute phase: a multicenter, randomized, double-blind, controlled trial

Repeated transcranial magnetic stimulation augmenting the treatment of schizophrenia with modified electroconvulsive therapy in the acute phase: a multicenter, randomized, double-blind, controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000035519
Enrollment
Unknown
Registered
2020-08-13
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

schizophrenia

Interventions

rTMS group:rTMS+MECT
sham rTMS group:sham rTMS+MECT

Sponsors

Tongji Hospital of Tongji University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Aged 18 to 65 years old, be able to cooperate with rTMS and MECT treatment; 2) Obtain the written informed consent of the subjects and family members/legal guardians; 3) Meet the diagnostic criteria for schizophrenia or schizophrenia in the American Diagnostic and Statistical Manual of Mental Disorders 4th Edition (DSM-IV) and the supporting SCID clinical examination, 4) Inpatients in the acute phase (ie, patients with first-onset schizophrenia and patients with recurrence of acute exacerbation of psychotic symptoms), of which the total course of relapse patients should be less than 5 years, and meet the following restrictions at the same time; 5) PANSS scale rough score >=70 points 6) In the following PANSS items, there are 2 or more items >=4 points (P1. Fantasy, P2. Association loose, P3. Hallucinations, P4. Excitement, P6. Suspicion/victimization, P7. Hostility, G4. Body tension, G8. No cooperation, G9. Unusual thinking content, G14. Impulse control disorder); 7) Maintain a stable dose of antipsychotics during rTMS treatment (the drugs are limited to atypical antipsychotics, and the dosage is equivalent to olanzapine 10-20mg/d); 8) Not currently receiving clozapine treatment or not receiving sufficient and sufficient course of clozapine treatment in the previous course.

Exclusion criteria

Exclusion criteria: 1) There are contraindications to rTMS, MECT or MRI: metal foreign bodies in the skull, persons with pacemakers, persons with cochlear implants, intracranial hypertension; 2) Mental retardation and nervous system diseases, major physical diseases; 3) History of brain trauma, MRI examination showed abnormal brain structure; 4) History of alcohol or drug abuse and dependence.

Design outcomes

Primary

MeasureTime frame
PANSS;

Secondary

MeasureTime frame
MCCB;GAF;MRI;MEG;

Countries

China

Contacts

Public ContactLu Zheng

Tongji Hospital of Tongji University

luzheng@tongji.edu.cn+86 18017311151

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026